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Statement of clinical relevance 
Classical Hodgkin lymphoma (cHL) commonly derives from preapoptotic germinal-center B cells. 
cHL cells are characterized by the loss of B cell markers and the varying expression of other 
hematopoietic lineage markers. This phenotypic variability and the lack of distinctive markers for 
cHL can prevent clear differentiation from related lymphomas.  
In this study, we combined complementary Cys-Glyco-CSC, Glyco-CSC and Lys-CSC technology 
variants for the in depth identification of cell surface proteins in cHL and non-Hodgkin lymphoma 
(NHL) cell lines seeking for distinctive patterns in cHL. Although, cHL and NHL cell lines have a 
similar overall composition of functional membrane protein groups, hierarchical clustering of the 
generated cell surfaceome maps separated cHL from NHL. Furthermore, B cell derived cHL cell lines 
were separated from T cell derived cHL cell lines in the hierarchical cluster analysis. To evaluate the 
potential of cell surface proteins for differentiation of cHL and NHL in a routine diagnostic setting, 
selected candidate markers were tested on tissue microarrays (TMAs). The TMA analysis indicated 
gamma-glutamyltranspeptidase 1 as a distinctive marker for cHL, which might be useful in an 
extended marker panel for the differential diagnosis of cHL.  
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Abstract 
Purpose 
Classical Hodgkin lymphoma (cHL) is characterized by a low percentage of tumor cells in a 
background of diverse, reactive immune cells. cHL cells commonly derive from preapoptotic 
germinal-center B cells and are characterized by the loss of B cell markers and the varying expression 
of other hematopoietic lineage markers. This phenotypic variability and the scarcity of currently 
available cHL-specific cell surface markers can prevent clear distinction of cHL from related 
lymphomas.  
Experimental design 
We applied the Cell Surface Capture (CSC) technology to directly measure the pool of cell surface 
exposed proteins in four cHL and four non-Hodgkin lymphoma (NHL) cell lines.  
Results 
More than 1 000 membrane proteins, including 178 CD annotated proteins, were identified and 
allowed the generation of lymphoma surfaceome maps. The functional properties of identified cell 
surface proteins enable, but also limit the information exchange of lymphoma cells with their 
microenvironment.  
Conclusions and clinical relevance 
Selected candidate proteins with potential diagnostic value were evaluated on a tissue microarray 
(TMA). Primary lymphoma tissue of 126 different B cell derived lymphoma cases were included in 
the TMA analysis. The TMA analysis indicated gamma-glutamyltranspeptidase 1 as a potential 
additional marker that can be included in a panel of markers for differential diagnosis of cHL versus 
NHL.  
www.clinical.proteomics-journal.com Page 4 Proteomics - Clinical Applications 
 
This article is protected by copyright. All rights reserved. 
 
1 Introduction 
Hodgkin lymphoma (HL) is one of the most frequent lymphomas in the Western world and it can be 
divided into classical HL and nodular lymphocyte-predominant HL (NLPHL). cHL accounts for 95% 
of the HL cases and it is characterized by a minority of neoplastic Hodgkin-Reed-Sternberg (HRS) 
cells and an extensive inflammatory cellular infiltrate [1, 2]. HRS cells usually derive from 
preapoptotic germinal-center B cells, and a small proportion of approximately 1-2% of cHL possibly 
originates from T cells [3, 4]. The differential diagnosis of cHL relies on a combination of 
morphology, immunophenotype, and genetic alterations according to the WHO classification [5]. The 
immunophenotype of HRS cells is characterized by the global loss of B cell markers and the aberrant 
expression of markers of other lineages. The limited number of known consistently expressed markers 
in cHL limits the number of markers included in panels for differential diagnosis. The limited 
immunophenotype can hamper distinction between cHL and related diseases, such as NLPHL, diffuse 
large B cell lymphomas (DLBCL) and their variant T cell rich large B cell lymphoma, and anaplastic 
large cell lymphoma. The overlapping phenotypes of these related diseases lead to so-called “grey 
zone” lymphomas, which are difficult to unambiguously classify [6]. Thus, extended panels with 
more markers are required for the accurate classification and sub-classification of lymphomas. Large 
scale investigation of surface markers in primary cHL is hampered by the scarcity of tumor cells. 
Therefore, better knowledge of the phenotype of cHL cells, obtained by the analysis of the 
surfaceome, may improve the understanding of cHL pathobiology and aims at facilitating the 
unambiguous classification as a base for a disease specific therapy. 
Mass spectrometry (MS) based proteomics enables the multiplexed identification and quantification 
of peptides in a discovery-driven analysis of the proteome [7]. Proteomic technologies are expected to 
revolutionize clinical practice but are not yet routinely applied for hematological malignancies [8]. 
Therefore, the application of proteomic technologies to cHL is still limited. Previous studies were 
either focused on the secretome of HL cells [9] or carried out using 2-dimensional gel electrophoresis 
that commonly leads to an underrepresentation of hydrophobic cell surface proteins [10-12]. 
Furthermore, Wallentine et al. extensively analyzed by LC-MS three different subcellular fractions of 
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two cHL cell lines and identified several hundred proteins per fraction [13]. However, membrane 
proteins were also in this study the smallest group of identified proteins. A recent, extensive shotgun 
proteomics study analyzed in-depth DLBCL cell lines, but included two cHL cell lines only as a 
reference [14]. 
The analysis of the cell surface proteome by MS is hampered by factors, such as the hydrophobicity 
of transmembrane proteins and the low relative abundance of cell surface proteins compared to 
intracellular proteins. We circumvented to a large extent these issues by developing the MS-based 
CSC technology [15], which was extended with complementary CSC technology variants [16]. Here, 
we applied the Cys-Glyco-CSC, Glyco-CSC and Lys-CSC technology variants for the multiplexed 
identification of cell surface proteins and the generation of surfaceome maps of cHL and NHL cells. 
By analyzing four cHL cell lines and four B cell derived NHL cell lines, we identified overall more 
than 1 000 membrane proteins, including 178 CD annotated proteins. Detailed surfaceome map 
analysis revealed surfaceome plasticity in-between the analyzed cell types, indicating potential 
diagnostic value. To test differentially expressed proteins between cHL and NHL with antibody-based 
probes, we created a TMA that contained 126 different patient lymphoma cases. The primary tissue 
spots on the TMA were derived from four different lymphoma subtypes, which allowed to readily 
assess the suitability of new cell surface markers to be included in an extended panel of markers for a 
better differential diagnosis of cHL versus NHL. 
2 Materials and methods 
Cell culture 
The cHL cell lines HDLM2, KMH2, L428, and L540 were kindly provided by Prof. Dr. Bernhard 
Odermatt (Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland) and the 
NHL cell lines HBL1, SUDHL4, SUDHL6, and U2932 were kindly provided by Dr. Liza Ho 
(Institute of Pathology, University of Geneva, Geneva, Switzerland). All cell lines were cultured in 
RPMI1640 (5% FCS, 100 units/ml penicillin, 100 µg/ml streptomycin; Sigma-Aldrich, Buchs, 
Switzerland) at 37 °C and 5% CO2.  
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CSC technology and LC-MS analysis  
Peptides of cell surface proteins were isolated with the Cys-Glyco-CSC/ Glyco-CSC and Lys-CSC 
technology and analyzed by LC-MS as described previously [16] and in the supplemental materials 
and methods.  
MS data analysis 
Raw data files from the MS instrument were converted with ReAdW into mzXML files [17] and 
mzXML files were searched with Sorcerer™-SEQUEST® [18] (version 3.5) against a concatenated 
protein database combining the human protein database of the UniProtKB/Swiss-Prot Protein 
Knowledgebase (version 56.9), the reversed sequences of all proteins, and common contaminants 
(41,104 protein entries). The database search criteria included: 40 ppm mass tolerance for the 
precursor ion, 0.5 Da mass tolerance for fragment ions, variable modifications of 0.984020 Da for 
asparagines (representing formerly N-glycosylated asparagines after deamidation through the PNGase 
F treatment), 145.019745 Da for lysines (representing 3-(carbamidomethylthio)propanoyl-tagged 
lysines), and 15.994920 Da for methionines (representing oxidized methionines), 
carbamidomethylation as static modification for cysteines, at least one tryptic terminus (K, R), and up 
to two missed cleavage sites. Statistical analysis for all LC-MS analyses of each cell line was 
performed using the Trans-Proteomic Pipeline TPP [19] v4.0 JETSTREAM rev 2 including 
PeptideProphet [20] and ProteinProphet [21]. Peptides with a PeptideProphet probability score of p ≥ 
0.05 were included in the subsequent ProteinProphet analysis. The ProteinProphet probability score 
was set to ≥ 0.9, which resulted in an average protein false discovery rate of less than 1% for all LC-
MS analyses for each cell line estimated by ProteinProphet. Proteins, which were only identified with 
single peptide identifications in the whole data set, were excluded from subsequent analyses. If 
peptide identifications led to an indistinguishable group of proteins, the first protein identifier was 
used for subsequent analyses and the remaining protein identifiers were listed in the supplemental 
tables. For the final complete data set with all cell lines, a protein false discovery rate of less than 2% 
and a peptide false discovery rate of less than 1% were estimated by the MAYU software [22]. The 
Skyline software [23] was used to create from the pepXML and mzXML files a spectral library 
containing MS/MS spectra with a cut-off score of 0.05. The sequence coverage of identified proteins 
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was determined with the Protein Coverage Summarizer (version 1.2.3365), which was downloaded 
from the website of the Biological MS Data and Software Distribution Center of the Pacific 
Northwest National Laboratory (Richland, WA, USA). CD numbers were mapped to 
UniProtKB/Swiss-Prot IDs according to the UniProtKB/Swiss-Prot Protein Knowledgebase cross-
reference table (version 57.0). Transmembrane helices of proteins were predicted with two algorithms, 
the TMHMM algorithm [24] (version 2.0) and the Phobius algorithm [25]. Protein identifications 
were denoted as membrane proteins, if at least one transmembrane helix algorithm predicted one or 
more transmembrane helices for the protein sequences. Furthermore, CD annotated proteins and 
proteins, which contained a lipid moiety-binding region according to the UniProtKB/Swiss-Prot 
Protein Knowledgebase, were also denoted as membrane proteins. Molecular functions, biological 
processes and pathways of identified proteins were assigned by the PANTHER (Protein ANalysis 
THrough Evolutionary Relationships) database [26] (version 6.1.1) based on the alphabetically first 
UniProtKB/Swiss-Prot AC number. Hierarchical cluster analysis was carried out with the Spotfire 
DecisionSite 9.1.1 software (TIBCO Software Inc., Palo Alto, CA, USA) based on protein 
identifications in the different cell lines. Unweighted pair-group method with arithmetic mean was 
chosen for clustering method and Euclidean distance for similarity measure. Proteins were excluded 
from the cluster analysis, if the total sum of assigned spectra over all cell lines was less than 10 
spectra.  
Patients 
Formalin fixed, paraffin embedded tissue biopsies of 144 patients with cHL (34 patients), FL 
(follicular lymphoma, 36 patients), DLBCL (36 patients), and MALTL (mucosa-associated lymphoid 
tissue lymphoma, 38 patients), which were diagnosed between 1998 and 2006, were retrieved from 
the files of the Institute of Surgical Pathology, University Hospital Zurich, Switzerland. Tissue cores 
of 18 patients were excluded (4 patients with cHL, 5 patients with FL, 3 patients with DLBCL, and 6 
patients with MALTL) due to loss of tumor tissue caused by the different cylinder lengths of the 
donor cores. All tissue cores on the TMA were typical representatives of the respective lymphoma 
subtypes. All cHL expressed CD30 and Pax5 indicating a B cell origin. There were no “grey zone” 
lymphomas included and all DLBCL were negative for CD30. The baseline characteristics of all 
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investigated subjects are shown in (supplemental Table S1). The study was approved by the Ethical 
Committee of the Canton of Zurich (StV 2-2007). 
Immunohistochemistry 
TMAs were constructed with 0.6 mm diameter cores of patient tissue as previously described [27]. 
TMAs were dewaxed in xylene, rehydrated through a graded ethanol series and washed in phosphate 
buffered saline. Antigen retrieval was achieved by heat treatment in a pressure cooker at 110 °C in 
citrate buffer (pH 6). Endogenous peroxidase activity was blocked by incubation in 0.6% H2O2 in 1:1 
(v/v) methanol-water for 10 minutes at room temperature. Subsequently, TMAs were incubated with 
protein blocking solution (Dako, Glostrup, Denmark) for 30 minutes at room temperature. Thereafter, 
slides were incubated with the appropriate dilution of primary antibody (supplemental Table S2). 
Immunodetection was performed with EnVision™+ Dual Link System-HRP (Dako) employing 3,3’-
diaminobenzidine/ H2O2 as chromogen. Sections were counterstained with hematoxylin. All biopsies 
were reviewed by two pathologists (M.T. and T.T.). The staining intensity for all proteins investigated 
was assessed in a four tiered system and graded as negative (-), weak (1+), moderate (2+), and strong 
(3+) [28]. Biopsies with weak, moderate or strong staining were stated as positive and biopsies with 
no staining were stated as negative. TMAs were scanned in 40X mode on a NanoZoomer (Hamamatsu 
Photonics, Shizuoka, Japan) and images were acquired using the web-based Distiller software 
(SlidePath, Dublin, Ireland). High magnification images were acquired on a Leica DM IRBE 
microscope (63X/0.7, Leica objective lenses) by a QImaging Retiga 1300 camera using QCapture 
v2.68.6 software (QImaging, Surrey, Canada). Contrast of images was adjusted with Adobe 
Photoshop CS4. 
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3 Results 
Generation of surfaceome maps of cHL and NHL 
Here, the surfaceome of four different cHL cell lines was analyzed with complementary CSC 
technology variants. Two of the cHL cell lines represent B cell derived cHL cell lines, KMH2 and 
L428, respectively [29, 30]. The other two cHL cell lines represent T cell derived cHL cell lines, 
HDLM2 and L540, respectively [31, 32]. The four cHL cell lines were compared with four B cell 
derived NHL cell lines. Two of the NHL cell lines represent activated B-like DLBCL cell lines, 
HBL1 and U2932, respectively [33, 34]. The other two NHL cell lines represent germinal center B-
like DLBCL cell lines, SUDHL4 and SUDHL6, respectively [35]. By applying the CSC technology, 
peptides from extracellular domains of cell surface proteins were isolated and identified by MS (Fig. 
1). Several hundred membrane proteins were identified with the CSC technology in each lymphoma 
cell line (Table I, supplemental Table S3). Overall, more than 1 000 membrane proteins, including 
178 bona fide cell surface exposed CD proteins, were identified in the eight lymphoma cell lines (Fig. 
2A; supplemental Table S4-6). cHL and NHL cells shared the majority of identified membrane 
proteins (57.7%) and CD proteins (54.5%). However, 459 membrane proteins were only identified in 
one lymphoma group, suggesting clear differences between cHL and NHL cells based on the CSC 
analyses. 
Functional protein classes in cHL and NHL 
Different classes of cell surface proteins are required for a cell to sense its microenvironment and to 
respond to external stimuli. Hence, proteins present at the cell surface reflect functional capacities of 
the cell. Categorization into molecular functions of all membrane proteins identified in cHL and NHL 
cell lines, respectively, showed a similar distribution of functional protein classes between the two 
lymphoma groups (Fig. 2B; supplemental Table S7). The largest functional protein groups included 
receptor proteins, defense/immunity related proteins, transporters, and signaling molecules. The 
number of spectra assigned to an identified protein can be used for the estimation of protein 
abundance [36]. The top three proteins identified with the highest number of spectra in all eight 
lymphoma cell lines were CD45, CD205, and CD54 for receptors, HLA class I, HLA class II, and 
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CD46 for defense/immunity related proteins, CD102, CD59, and CD37 for signaling molecules, and 
CD298, cholin transporter-like protein (CTL2), and neutral amino acid transporter A (SATT) for 
transporters. The overlapping proteins found in cHL and in NHL cell lines showed a strong 
enrichment of defense/immunity related proteins, which are depleted in the group of non-overlapping 
proteins between cHL and NHL (supplemental Fig. S1). In summary, the CSC analyses suggest that 
cHL and NHL cells have a similar overall composition of functional membrane protein groups and 
have high abundant proteins in common. 
Comparative surfaceome map analysis of cHL and NHL 
Although the distributions of functional protein groups were very similar for cHL and NHL, the 
comparison of identified proteins showed that the composition of each functional protein group 
differed between cHL and NHL. For example, peptides of the receptors CD30, IL18R, and CRLF2, 
respectively, were only identified in cHL and not in NHL cell lines. CD30 was identified in each cHL 
cell line with more than 100 assigned spectra with the CSC technology (supplemental Table S4). In 
combination with other receptors, CD30 is important for the activation of the NF-κB, PI3K/Akt, and 
MAPK/Erk signaling cascade [1, 2]. The CSC technology readily identified the CD30 protein, which 
is a hallmark of HRS cells and it is commonly used as a marker for the differential diagnosis of cHL. 
Cytokine receptors in HRS cells activate the JAK/STAT signaling pathway and signaling of IL13R 
and IL21R are known to be important for proliferation of HRS cells [37, 38]. Interestingly, in addition 
to IL13R and IL21R, several other cytokine receptors including IL18R and CRLF2 were identified in 
cHL cells with the CSC technology.  
The surfaceome analyses with the CSC technology showed differences in protein identifications not 
only between cHL and NHL cell lines but also within the group of cHL cell lines. Several receptors 
and receptor ligands that are crucial components in different signal transduction pathways were 
identified only in the two B cell derived cHL cell lines, KMH2 and L428. For example, two receptor 
tyrosine kinases, EphB2 (EPHB2) and the previously described CD136 (RON) [39], were identified 
only in B cell derived cHL cell lines. Interestingly, Notch1 (NOTC1) and Notch2 (NOTC2) were 
identified in all eight lymphoma cell lines, but the two transmembrane and GPI-anchored, respectively, 
Notch ligands, Jagged1 (JAG1) and Contactin1 (CNTN1), were identified only in the B cell derived 
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cHL cell lines. In the T cell derived cHL cell lines, HDLM2 and L540, several T cell antigens were 
identified including CD2, CD4, and CD90. However, these T cell antigens were not consistently and 
not exclusively identified in the T cell derived cHL cell lines. These results show the highly variable 
phenotype of cHL. Nonetheless, hierarchical cluster analysis of identified membrane proteins with 
more than 10 assigned spectra led to a separation of B cell derived from T cell derived cHL cell lines 
and also to a separation of cHL from NHL cell lines (Fig. 2C; supplemental Table S8-10), which 
suggests that the membrane protein expression profile is characteristic for lymphoma subgroups. 
In addition to proteins exclusively identified in only one lymphoma group or lymphoma subgroup, 
many proteins were identified with different numbers of assigned spectra between the two lymphoma 
groups indicating a difference in protein abundances. An interesting example is the gamma-
glutamyltranspeptidase 1 (GGT1, CD224), which is widely used as a diagnostic marker for liver 
disease. GGT1 was identified overall with 142 spectra in the four cHL cell lines but with less than 10 
spectra in only one NHL cell line (supplemental Fig. S2, supplemental Table S4). Already in the 
1980s, it was shown cytochemically that HRS cells exhibit a very strong GGT1 activity [40, 41], but 
ever since GGT1 expression in HRS cells did not attract a lot of attention in HL research. The 
hepatocyte growth factor receptor (MET) that is encoded by the proto-oncogene c-met was also 
identified with a large quantitative difference of assigned spectra between cHL and NHL cells. MET 
was previously described to be expressed in HRS cells [42] and the CSC technology identified MET 
predominantly in cHL cell lines with a difference of 288 assigned spectra compared with 12 assigned 
spectra for the protein identification in cHL and NHL cells, respectively (supplemental Fig. S2, 
supplemental Table S4). Besides the aberrant expression of cell surface proteins, B cell derived HRS 
cells are characterized by the loss of B cell markers [1, 2]. Consistent with this expectation, the B cell 
markers, CD19, CD20, CD22, CD79a, and CD79b, were not identified with the CSC technology in 
the cHL cell lines but were identified in all NHL cell lines (Fig. 3).  
In summary, these examples of identified proteins show that the CSC-based surfaceome mapping 
enabled an extensive phenotyping of cHL and NHL cell lines far beyond what is usually achieved 
with antibody-based technologies. Furthermore, the comparative analysis reliably recapitulated known 
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phenotypic characteristics of cHL cells and also identified cell surface proteins with little prior 
information about their functions in cHL. 
Tissue microarray analysis 
Additional cHL markers that extend the current marker panel may significantly contribute to facilitate 
and bolster the reliable diagnosis of cHL. In order to investigate if identified proteins by LC-MS are 
useful for the differential diagnosis of cHL versus other B cell derived hematological malignancies, 
in-house developed TMAs were immunohistochemically analyzed for the expression of candidate 
classification markers. The TMAs contained 126 different lymphoma cases including 30 cHL, 33 
DLBCL, 31 FL, and 32 MALTL cases with different patient characteristics (supplemental Table S1). 
From numerous tested antibodies, only two paraffin-reactive antibodies were identified that showed 
reliable staining properties. The candidate classification markers, GGT1 and MET, were identified by 
LC-MS predominantly in cHL cell lines (supplemental Fig. S2). Dilutions of antibodies against the 
two candidate classification markers were optimized on a cell line microarray containing all eight 
lymphoma cell lines that had been analyzed with the CSC technology (supplemental Table S2). Then, 
TMAs were analyzed immunohistochemically for the expression of GGT1 and MET, respectively 
(Fig. 4). Non-informative arrayed tissue samples due to missing tissue or lack of tumor cells in the 
arrayed tissue cores were excluded. Expression of all two candidate classification markers was 
detected in HRS cells with a cytoplasmic and membranous staining (Fig. 4B-C). GGT1 was 
predominantly expressed in cHL with 100% positive cHL, 27% positive DLBCL, 3% positive FL, and 
3% positive MALTL cases (Table II). The expression of MET was more variable with several 
positive cases in all four lymphoma groups. Thus, expression of both candidate classification markers 
derived from the proteomic comparison of cHL and NHL cell lines were detected in primary patient 
samples. 
www.clinical.proteomics-journal.com Page 13 Proteomics - Clinical Applications 
 
This article is protected by copyright. All rights reserved. 
 
4 Discussion 
Cell surface proteins are readily accessible and well suited as diagnostic and therapeutic targets. 
Currently, the panel of protein markers used for differential diagnosis of cHL is still limited. This lack 
of classification markers is partially due to difficulties to comprehensively compare neoplastic cells 
on the protein level. Here, we show that the CSC technology enabled the generation of surfaceome 
maps of cHL and NHL cell lines to a depth of more than 1 000 membrane proteins, including 178 CD 
proteins. Hierarchical cluster analysis of protein identifications led to a separation of cHL from NHL 
cell lines and to a separation of B cell derived from T cell derived cHL cell lines (Fig. 2C), which 
suggests that the membrane protein expression profile is characteristic for lymphoma subgroups. 
Furthermore, the differential surfaceome map analysis identified in cHL and NHL cell lines numerous 
receptors that represent crucial components of different signal transduction pathways, such as the NF-
κB, PI3K/Akt, MAPK/Erk, JAK/STAT, and Wnt/beta catenin signaling pathway. 
Comparative analysis of identified proteins in cHL and NHL cell lines reliably recapitulated known 
phenotypic characteristics of cHL. The loss of B cell markers and the expression of CD30, CD40, 
CD54, CD80, and CD274 [1, 2], to name several examples, were identified in the CSC-based 
surfaceome maps of cHL cells (Fig. 3). CD30 is commonly used as a marker for the differential 
diagnosis of cHL. More recently, CD30 is also used as a drug target by the antibody-drug conjugate 
brentuximab vedotin. Thus, the CSC technology enabled the reliable identification of the cHL marker 
CD30 that is exploited for diagnosis and targeted therapeutic intervention. The characteristic 
expression of CD15 in cHL, which is often used in marker panels for differential diagnosis of cHL, 
was not detected with our CSC-based protein identification approach, since CD15 represents the 
trisaccharide 3-fucosyl-N-acetyl-lactosamine, which is refractory to the applied peptide selection 
method.  
Apart from proteins that are known to be expressed in cHL, numerous proteins with little prior 
information about their functional role in cHL were identified exclusively in cHL cell lines, such as 
CRLF2. CRLF2 is a type I cytokine receptor and it forms together with IL7R the heterodimeric 
receptor for thymic stromal lymphopoietin (TSLP) [43]. Interestingly, binding of TSLP to its receptor 
induces activation of STAT5 and STAT5 activity is known to induce in human tonsillar B cells 
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phenotypic changes similar to HRS cells [38, 43]. Thus, CRLF2 might play through STAT5 a role in 
Hodgkin lymphomagenesis [44]. It was also shown that CRLF2 overexpression is associated with 
poor outcome in B cell acute lymphoblastic leukemia [45].  
Furthermore, proteins were identified with higher abundances based on spectral counting in cHL than 
in NHL cell lines, such as GGT1 and MET. GGT1 belongs to the family of gamma-glutamyl 
transferases (GGTs), which are post-translationally processed to form heavy and light chain 
containing single transmembrane spanning proteins. Drugs and carcinogens induce GGT expression 
in the liver and assays for GGT activity are widely used in the clinic to measure liver cell damage. 
GGTs are crucial for the metabolism of glutathione and the conversion of leukotriene C4 into 
leukotriene D4. Furthermore, there are indications that GGT also plays a crucial role in drug 
resistance of cancer cells [46]. The receptor tyrosine kinase MET is a disulfide-linked alpha/beta 
heterodimer and the beta-chain spans the plasma membrane. MET acts as a receptor for the 
hepatocyte growth factor, and it was speculated that ligand binding may lead to cytokine release in 
MET positive HRS cells [47]. MET is known to be important for the regulation of adhesion and 
migration of activated B cells and it is also expressed in germinal center centroblasts [48, 49]. In 
addition to the here in more detail discussed proteins, numerous other proteins were identified that 
represent interesting candidates to be tested for the differential diagnosis of cHL versus NHL, since 
they were identified either in only one lymphoma group or with a large quantitative difference 
between the lymphoma groups based on the number of assigned spectra for protein identifications.  
Selected candidate classification markers, against which paraffin-reactive antibodies with reliable 
staining properties were available, were analyzed on TMAs containing 126 different lymphoma cases. 
The two candidate proteins for cHL, GGT1 and MET, were detected immunohistochemically in 
primary lymphoma tissue. GGT1 was detected in lymphoma cells of every single cHL patient but in 
contrast only in a minority of DLBCL patients, in a single FL patient and a single MALTL patient. 
This finding and the importance of GGT1 for the conversion of leukotriene C4 into leukotriene D4 
might represent a very interesting link to the extensive inflammatory cellular infiltrate that is 
characteristic for cHL. Expression of MET was more heterogeneous and the limited number of 
patients on the TMA did not allow to deduce conclusive characteristics of MET positive patients.  
In summary, we were able to in-depth analyze the cell surface proteome plasticity of cHL and NHL 
cell lines by applying the CSC technology. Our analysis identified new candidates that could be 
included in marker panels for the differential diagnosis of cHL versus NHL. A plethora of interesting 
protein identifications can be found in the data set, which could generate new hypotheses and 
represent the starting point for new studies to better understand the pathobiology of cHL and NHL. 
Prospective studies, including the analysis of a larger patient cohort with an extended marker panel 
that includes several of the candidate proteins, should contribute to more unambiguously differentiate 
cHL from NHL. 
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FIG. 1. The CSC technology uses an affinity labeling strategy to enrich for peptides from the 
extracellular domains of cell surface proteins. This enrichment strategy involves [1] 
complementary biotinylation of cell surface proteins with different reactive biotin derivatives, [2] cell 
homogenization and membrane isolation, [3] protein digestion, [4] streptavidin affinity enrichment of 
biotinylated peptides, [5] peptide release, [6] peptide analysis by LC-MS and peptide identification. 
 
 
www.clinical.proteomics-journal.com Page 20 Proteomics - Clinical Applications 
 
This article is protected by copyright. All rights reserved. 
 
FIG. 2. CSC analysis of cHL and NHL cell lines. A) Venn diagrams showing overlapping membrane 
and CD protein identifications in cHL and NHL cells. B) Distribution of PANTHER molecular 
functions of identified membrane proteins in cHL and NHL cells. C) Hierarchical cluster analysis of 
identified membrane proteins in cHL and NHL cells. The hierarchical cluster analysis was restricted 
to 709 membrane proteins that were identified with at least 10 assigned spectra in the whole data set. 
Each row represents one protein and each column represents one cell line. Protein identifications or 
missing protein identifications are depicted in black and white, respectively. The distribution of CD 
annotated proteins is shown in red.  
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FIG. 3. Extensive CD phenotyping of cHL and NHL cells. Overview of 146 selected CD proteins, 
which were identified with a sum of at least 10 assigned spectra in the four cHL cell lines or in the 
four NHL cell lines. The inner color code of the squares visualizes the number of assigned spectra per 
CD protein for cHL cells (upper squares) and NHL cells (lower squares). 
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FIG. 4. Immunohistochemical detection of GGT1 and MET in cHL. (A) Schematic overview of 
the TMA containing tissue samples of 126 different lymphoma cases. (B) Immunostainings for GGT1 
and (C) MET with hematoxylin counterstainings in HRS cells in low magnification (image on the left) 
and high magnification (image on the right).  
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TABLES 
TABLE I 
Number of identified membrane proteins and CD proteins in cHL and NHL cell lines 
 
Cell line Lymphoma Membrane proteins CD proteins 
KMH2 cHL (B cell derived, MC) 536 94 
L428 cHL (B cell derived, NS) 588 92 
HDLM2 cHL (T cell derived, NS) 512 94 
L540 cHL (T cell derived, NS) 459 94 
HBL1 DLBCL (ABC) 586 97 
U2932 DLBCL (ABC) 510 107 
SUDHL4 DLBCL (GCBC) 464 83 
SUDHL6 DLBCL (GCBC) 457 95 
MC, mixed cellularity; NS, nodular sclerosis; ABC, activated B-like; GCBC, germinal center B-like 
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TABLE II 
TMA analysis of GGT1 expression and MET expression in lymphoma patients 
 
Lymphoma 
GGT1 MET 
n N (%) P (%) n N (%) P (%) 
DLBCL 33 24 (73) 9 (27) 33 23 (70) 10 (30) 
FL 30 29 (97) 1 (3) 30 9 (30) 21 (70) 
HL 28 0 (0) 28 (100) 25 8 (32) 17 (68) 
MALTL 32 31 (97) 1 (3) 31 24 (77) 7 (23) 
n, number of patients; N, negative; P, positive 
